Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Summary

To learn if the combination of 2 study drugs, CB-103 and venetoclax, can help to control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients

Timeline

Start

2023-04-06

Primary completion

2024-08-12

Completion

2024-08-12

Outcome

Outcome not reported

Stopped: “The sponsor requested termination due to internal reprioritization of resources.”

Drugs

Indications